University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Eric J. Small, MD

Eric J. Small, MD

Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF
Deputy Director and Chief Scientific Officer; Program Leader, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center
Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

My interests lie in clinical and translational research in advanced prostate cancer, including trial design, and development of novel agents. I piloted the early trials targeting the androgen receptor in advanced prostate cancer, developing ketoconazole and contributing to an understanding of its mechanisms of activity and resistance. I subsequently was centrally involved with the development of two novel androgen signaling inhibitors, abiraterone acetate and apalutamide, from first in human studies to FDA approval.

I have also been involved in the early application of immunotherapy to prostate cancer, developing sipuleucel T from first in human studies through FDA

approval, and undertaking the first in human testing of ipilimumab, the first immune check point inhibitor to be clinically developed.

Understanding the mechanisms of resistance in advanced prostate cancer has been a research focus. I was principal investigator of a $10 million multi-center Stand Up to Cancer (SU2C)/Prostate Cancer Foundation Dream Team Award undertaking deep genomic characterization of prostate cancer metastases, in order to elucidate patterns of resistance in abiraterone and/or enzalutamide

treated patients. Important observations from this, and subsequent work have included unexpectedly high prevalence rates of treatment associated small cell/neuroendocrine prostate cancer (t-SCNC), as well key structural variants which contribute to progression of castration-resistant disease, observed in the largest Whole Genome Sequencing series to date of metastatic advanced prostate cancer specimens.

I hold a number of leadership roles, serving as Leader of the UCSF Prostate Cancer Program, and as Deputy Director of the UCSF Helen Diller Family Comprehensive Cancer Center. I have served as Chief of the Division of Hematology and Oncology in the UCSF Department of Medicine for 10 years, and most recently have assumed the position of Chief Scientific Officer in the UCSF Helen Diller Family Comprehensive Cancer Center. Nationally, I serve on the ASCO Board of Directors, and chair a number of External Advisory Boards for other Cancer Centers.

Throughout all of these activities, is a deep and abiding commitment to mentorship and support of the next generation of cancer clinicians and investigators.

Education

Stanford University, Stanford, CA, BS, 1980, Biology
Case Western Reserve University of Medicine, Cleveland, Ohio, MD, 1985, Medicine
Beth Israel Hospital, Boston, MA, Internship and Residency, 1988, Internal Medicine
University of California San Francisco, CA, Fellowship, 1991, Hematology/Oncology


Professional Experience

  • 1982-1983
    Pathology Fellowship, Department of Pathology, Case Western Reserve Univ., Cleveland, OH
  • 1985-1988
    Internal Medicine Internship and Residency Training Program, Beth Israel Hospital, Boston, MA
  • 1988-1989
    Clinical Fellow, Cancer Research Institute, UCSF, San Francisco, CA
  • 1989-1991
    Research Fellow, Cancer Research Institute, (Dr. Marc Shuman) UCSF, San Francisco, CA
  • 1991-1997
    Assistant Clinical Professor of Medicine, UCSF, San Francisco, CA
  • 1991-present
    Head, Urologic Medical Oncology, Division of Hematology/Oncology, UCSF, San Francisco, CA
  • 1996-present
    Co-Director, Urologic Oncology Program, UCSF, San Francisco, CA
  • 1997-2001
    Associate Clinical Professor of Medicine and Urology, UCSF, San Francisco, CA
  • 1999-present
    Chair, Genitourinary Committee, Cancer and Leukemia Group B (CALGB)
  • 2001-present
    Professor in Residence of Medicine and Urology, UCSF, San Francisco, CA
  • 2007-2009
    Interim Chief, Division of Hematology and Oncology, UCSF, San Francisco, CA
  • 2007-present
    Director, Investigational Trials Resource, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2009-present
    Chief, Division of Hematology/Oncology, UCSF, San Francisco, CA
  • 2009-present
    Deputy Director and Director of Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 1978
    Biomedical Research Grant, The Jackson Laboratory, Bar Harbour, ME
  • 1980
    NIH Research Support Grant, Case Western Reserve University, Cleveland, OH
  • 1984
    Alpha Omega Alpha Honor Medical Society
  • 1997
    Prostate Cancer Foundation Therapy Consortium
  • 2006-present
    Stanford W. and Norman R. Ascherman Endowed Chair

Selected Publications

  1. George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019 Aug 09.
    View on PubMed
  2. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019 Jul 30.
    View on PubMed
  3. Desai A, Small EJ. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Future Oncol. 2019 Jun 11.
    View on PubMed
  4. Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2019 May 03.
    View on PubMed
  5. Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS. Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw. 2019 May 01; 17(5):515-521.
    View on PubMed
  6. Raghavan K, Wen KW, Small EJ, Ha P, Flavell RR. Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT. Clin Nucl Med. 2019 May; 44(5):e367-e369.
    View on PubMed
  7. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 May 01; 17(5):479-505.
    View on PubMed
  8. Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Apr 22.
    View on PubMed
  9. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Mar 28.
    View on PubMed
  10. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Mar 27.
    View on PubMed
  11. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 Jun; 17(6):1235-1240.
    View on PubMed
  12. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 Feb 25.
    View on PubMed
  13. Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. Clin Nucl Med. 2019 Jan; 44(1):e28-e32.
    View on PubMed
  14. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019 Feb 10; 37(5):403-410.
    View on PubMed
  15. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 Apr 15; 25(8):2450-2457.
    View on PubMed
  16. Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ. Reply to A. Dalla Volta et al. J Clin Oncol. 2019 Feb 01; 37(4):351-352.
    View on PubMed
  17. Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2018 Nov 21.
    View on PubMed
  18. Borno HT, Small EJ. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2019 Feb; 15(6):591-599.
    View on PubMed
  19. Koshkin VS, Small EJ. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Dec; 10(12):445-454.
    View on PubMed
  20. Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer Prostatic Dis. 2018 Nov 01.
    View on PubMed

Go to UCSF Profiles, powered by CTSI